Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Stroke. 2006;37:2368-2371
Published online before print August 10, 2006, doi: 10.1161/01.STR.0000236496.30106.4b
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
37/9/2368    most recent
01.STR.0000236496.30106.4bv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilczak, N.
Right arrow Articles by De Keyser, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilczak, N.
Right arrow Articles by De Keyser, J.
Related Collections
Right arrow Thrombolysis
Right arrow Acute Cerebral Infarction
Right arrow Emergency treatment of Stroke
Right arrow Fibrinolysis

(Stroke. 2006;37:2368.)
© 2006 American Heart Association, Inc.

Short Communication

Intravenous Tissue Plasminogen Activator in Patients With Stroke Increases the Bioavailability of Insulin-Like Growth Factor-1

Nadine Wilczak, PhD; Jan Willem Elting, MD; Daniel Chesik, PhD; Ido P. Kema, MD Jacques De Keyser, MD

From the Departments of Neurology (N.W., J.W.E., D.S., J.D.) and Laboratory Medicine (I.P.K.), University Medical Center Groningen, Groningen, The Netherlands.

Correspondence to Professor Jacques De Keyser, Department of Neurology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands. E-mail j.h.a.de.keyser{at}neuro.umcg.nl

Background and Purpose— Insulin-like growth factor (IGF)-1 has potent neuroprotective properties. We investigated the effects of intravenous administration of tissue plasminogen activator (tPA) on serum levels of IGF-1 and IGF-binding protein (IGFBP)-3 in patients with acute ischemic stroke.

Methods— Serum levels of total IGF-1, free IGF-1, and IGFBP-3 were measured by radioimmunoassay in 10 patients with ischemic stroke treated with intravenous tPA (0.9 mg/kg body weight) and 10 untreated controls.

Results— During tPA treatment, total IGF-1 and IGFBP-3 serum levels did not change, but there was an &70% increase in free IGF-1 serum levels from 0.98±0.25 at baseline to 1.69±0.18 nmol/L at the end of the 1-hour infusion (P=0.01).

Conclusions— Intravenous therapy with tPA enhances the bioavailability of IGF-1.


Key Words: acute stroke • insulin-like growth factor 1 • neuroprotection • thrombolysis • tissue plasminogen activator






Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.